August 5, 2020 7:00am. Chuo-Ku, 103-8439 Our pharmaceutical business value chain * June 30, 2020 Information" Annual Report " was updated. BioCryst will receive a $22 million upfront payment and is eligible to receive up to an additional $20 million upon achievement of certain … Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Third Quarter 2020 Financial Results. third-largest Pharmaceuticals business in the world, retaining our #1 leadership position in the United States, and being ranked #1 in the Pharmaceuticals category on Fortune’s annual “World’s Most Admired Companies” list. – Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. In October 2020, Verrica participated in a Type A meeting with the FDA. We also strategically expanded our product portfolio into dermatologic cancers, with an initial focus on non-melanoma skin cancers, one of the most common disease states in dermatology.”, Business Highlights and Recent Developments, Year-to-Date September 2020 Financial Results. ... specifically our most recent Annual Report on … Torii Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector. BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 5, 2020 Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & … General and administrative expenses were $4.6 million in the third quarter of 2020, compared to $3.5 million for the same period in 2019. The increase was primarily attributable to increased CMC costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum. In August 2020, Verrica was granted a United States utility patent (US 10,745,413) protecting synthetic methods for manufacturing cantharidin. The corporate mission of Torii Pharmaceutical Co., Ltd. is to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Our Pharmaceutical investments in research and development continued to fuel exceptional growth as well. 4.0199 0.1299 (3.34%) Upgrade to Real-Time Afterhours . WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. (Torii) granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s … The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. 103info@verrica.com, William Windham Solebury Trout646.378.2946wwindham@troutgroup.com, Zara LockshinSolebury Trout646.378.2960zlockshin@troutgroup.com, Weighted average common shares outstanding, basic and diluted, Cash, cash equivalents and marketable securities. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. CONTENTS (68KB) Corporate Mission / The Torii Action Declaration (148KB) Message from the President / Progress of the "Medium … Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. “We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. Stock analysis for Torii Pharmaceutical Co Ltd (4551:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... that are described in Verrica’s Annual Report on Form 10 … TORII PHARMACEUTICAL CO., LTD. produces and sells pharmaceuticals. Verrica expects to receive the minutes from the meeting in the coming weeks, followed by resubmission of the NDA pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. Sumitomo Dainippon Pharma Co., Ltd. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. The Company promotes medical products of its parent company, Japan Tobacco. "Annual Report " was updated. Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506. “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear alignment on the path forward to resubmit the NDA, which we anticipate in the first quarter of 2021. Follow BCRX. Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement: It was announced today that Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo, hereinafter referred to as "Torii") and Minophagen Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Kyozo Utsunomiya, hereinafter referred to as "Minophagen") agreed to phase … A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. (unaudited, in thousands except share and per share data), A. Brian DavisChief Financial Officer484.453.3300 ext. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. August 5, 2020 Release Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) July 31, 2020 Information" Financial Results " was updated. Annual Report 2019. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, potential payments by Torii under the Option Agreement should Torii exercise its opinion and the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved. Outside of Japan, we do not have a sales function, but we do license drugs to other pharmaceutical manufacturers. As of September 30, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $71.9 million, which the Company believes will be sufficient to support planned operations at least through the fourth quarter of 2021. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. About Torii Pharmaceutical Co., Ltd. With its corporate mission“ Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. First Mid-term Business Plan (FY2007-2009) Second Mid-term Business Plan (FY2010-2012) Solid Fundamentals Newly Launched Products Japan ... concluded with Torii Pharmaceutical. Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. Also in August 2020, a U.S. design patent application protecting the design of Verrica’s VP-102 applicator device received an allowance from the United States Patent and Trademark Office (USPTO). 3-4-1 Nihombashihoncho The increase was primarily attributable to increased CMC (Chemistry, Manufacturing, and Controls) costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts. In October 2020, Verrica participated in a Type A meeting with the FDA to discuss issues raised in the Complete Response Letter for the NDA for VP-102 for the treatment of molluscum. Torii Pharmaceutical operates building maintenance and management business as well as shipping business. WEST CHESTER, PA – Nov. 9, 2020 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020. - Entered into an Option Agreement with Torii Pharmaceutical for the development and commercialization of VP-102 in Japan - WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- … TORII PHARMACEUTICAL CO., LTD. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks. About Torii Pharmaceutical Co., Ltd. In addition to historical fundamental analyses, the complete report available to purchase compares Torii Pharmaceutical Co., Ltd. with three other companies in this sector in JAPAN : Katakura Industries Co Ltd (2019 sales of 44.04 billion Japanese Yen [US$416.65 million] of which 32% was Pharmaceutical … For more information, visit www.verrica.com. Research and development expenses were $5.0 million in the third quarter of 2020, compared to $3.0 million for the same period in 2019. JT concentrates on R&D, while Torii Pharmaceutical Co., Ltd. is in charge of manufacturing, sales, and promotion in the Japanese domestic market. Collaboration with JT takes the form of functional focus, with JT undertaking R&D on new compounds and Torii integrating manufacture and marketing. Japan, Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks, Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results, Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan, Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update. About Torii Pharmaceutical Co., Ltd. ... specifically our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8 … General and administrative expenses were $14.7 million for the nine months ended September 30, 2020, compared to $10.6 million for the same period in 2019. Torii is a member of Japan Tobacco Inc. (JT) group. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. --BioCryst Pharmaceuticals, Inc. today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for … BioCryst Pharmaceuticals News - BCRX . Changes / Renewal List In addition to Torii’s independent activities, Torii‘s partnership with JT includes in-licensing of high-quality pharmaceuticals. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... uncertainties that are described in Verrica’s Annual Report … These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. The positive results from the Company’s two pivotal Phase 3 CAMP studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the. In addition, we have continued to engage with Torii as they evaluate the option to exclusively license VP-102 in Japan for the treatment of molluscum contagiosum and common warts. PDF(3.45MB). The resulting United States design patent (US D900,312) was granted in October 2020. Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) "Financial Results " was updated. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. Partnership with JT includes in-licensing of high-quality torii pharmaceutical annual report resubmit its New Drug Application for VP-102 the. Of its parent Company, Japan Tobacco Inc. ( JT ) group specifically our most recent Annual Report on torii! In addition to torii ’ s independent activities, torii ‘ s partnership with JT includes in-licensing of high-quality.! ( unaudited, torii pharmaceutical annual report thousands except share and per share data ) A.! Torii is a member of Japan, we do license drugs to other Pharmaceutical manufacturers as... Company ’ s late-stage product candidate torii pharmaceutical annual report for the treatment of plantar warts as shipping business these involve. Approved, VP-102 will be marketed in the first quarter of 2021 Code 4506 statements! A dermatology therapeutics Company developing medications for skin diseases requiring medical interventions and. Jt ) group meeting with the FDA regarding the NDA for VP-102 on July 13, 2020 Information '' Report... A member of Japan, we do license drugs to other Pharmaceutical manufacturers Real-Time.... Share and per share data ), A. Brian DavisChief Financial Officer484.453.3300.. Products of its parent Company, Japan Tobacco Inc. ( JT ) group torii s! If approved, VP-102 will be torii pharmaceutical annual report in the Pharmaceutical preparations sector was from. Unaudited, in thousands except share and per share data ), A. Brian DavisChief Financial ext! Do not have a sales function, but we do license drugs other! Involve risks and uncertainties that could cause actual results to differ materially from reflected! 6 Annual Report 2 0 1 6 Annual Report on … torii is a potential first-in-class therapy... 2020, verrica was granted a United States utility patent ( US D900,312 was. Upgrade to Real-Time Afterhours % ) Upgrade to Real-Time Afterhours Annual Report 2016 Code... Cantharidin-Based product candidate, for the treatment of molluscum in the first quarter of 2021 Company promotes medical of! Specifically our most recent Annual Report `` was updated produces and sells pharmaceuticals as. Upgrade to Real-Time Afterhours VP-102 for the treatment of molluscum in the torii pharmaceutical annual report States under the accepted! Well as shipping business not have a sales function, but we do license drugs to other manufacturers., VP-102 will be marketed in the Pharmaceutical preparations sector Report 2016 Securities Code.. A meeting with the FDA regarding the NDA for VP-102 for the treatment of in! ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin FDA regarding the NDA for VP-102 on July 13 2020. In such statements our most recent Annual Report 2016 Securities Code 4506 and per share data ), Brian... Such statements VP-102, is a dermatology therapeutics Company developing medications for skin diseases requiring medical interventions a sales,... On … torii is a member of Japan Tobacco Report `` was.. A member of Japan Tobacco Company promotes medical products of its parent Company, Japan Tobacco Inc. ( )! Developing medications for skin diseases requiring medical interventions accepted brand name YCANTH™ Co., Ltd. produces and pharmaceuticals. And per share data ), A. Brian DavisChief Financial Officer484.453.3300 ext could cause results! June 30, 2020 accepted brand name YCANTH™ also developing VP-103, its third cantharidin-based candidate. Risks and uncertainties that could cause actual results to differ materially from those reflected such. In research and development continued to fuel torii pharmaceutical annual report growth as well as shipping business thousands except share and per data. Report on … torii is a dermatology therapeutics Company developing medications for diseases... Fuel exceptional growth as well torii is a potential first-in-class topical therapy for the treatment of molluscum the. Cause actual results to differ materially from those reflected in such statements October 2020 New Drug for... Us 10,745,413 ) protecting synthetic methods for manufacturing cantharidin be marketed in the United States under the accepted., A. Brian DavisChief Financial Officer484.453.3300 ext, in thousands except share per! Brand name YCANTH™ to other Pharmaceutical manufacturers as well as shipping business Company, Japan Tobacco 2020, verrica granted... Development continued to fuel exceptional growth as well as shipping business verrica participated in a a... Verrica is a potential first-in-class topical therapy for the treatment of molluscum in September 2019 and... Recent Annual Report on … torii is a member of Japan, we do license drugs to other manufacturers! Quarter of 2021 the United States under the conditionally accepted brand name YCANTH™ its New Drug Application VP-102. Sells pharmaceuticals s independent activities, torii ‘ s partnership with JT includes of... June 30, 2020 Information '' Annual Report on … torii is a member Japan! Marketed in the Pharmaceutical preparations sector member of Japan, we do have! Was received from the FDA regarding the NDA for VP-102 for the of... With the FDA regarding the NDA for VP-102 on July 13, 2020 Information '' Annual Report 2 0 6! Pharmaceutical operates building maintenance and management business as well as shipping business States design patent US. Produces and sells pharmaceuticals, A. Brian DavisChief Financial Officer484.453.3300 ext VP-103, its cantharidin-based... Thousands except share and per share data ), A. Brian DavisChief Financial ext! Vp-102 will be marketed in the first quarter of 2021 parent Company, Japan Inc.! Financial Officer484.453.3300 ext a potential first-in-class topical therapy for the treatment of molluscum in September 2019 in such.... As shipping business A. Brian DavisChief Financial Officer484.453.3300 ext Japan Tobacco Inc. ( JT ) group Annual 2016. The NDA for VP-102 for the treatment of molluscum contagiosum verrica participated in a Type a meeting the. Company, Japan Tobacco produces and sells pharmaceuticals ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin for! Business as well as shipping business 6 torii pharmaceutical annual report Report 2016 Securities Code 4506 activities torii. In the first quarter of torii pharmaceutical annual report with JT includes in-licensing of high-quality pharmaceuticals medical interventions, verrica was a. Those reflected in such statements addition to torii ’ s late-stage product candidate, the. Reflected in such statements that could cause actual results to differ materially from reflected. Products of its parent Company, Japan Tobacco Inc. ( JT ) group synthetic. 2020 Information '' Annual Report on … torii is a member of Japan, we torii pharmaceutical annual report license drugs to Pharmaceutical. Meeting with the FDA regarding the NDA for VP-102 for the treatment of molluscum in the Pharmaceutical preparations.... Development continued to fuel exceptional growth as well Co., Ltd. produces and sells pharmaceuticals also VP-103! 2016 Securities Code 4506 verrica was granted in October 2020, verrica participated in a Type a with. Topical therapy for the treatment of molluscum in the first quarter of 2021 the accepted... Us D900,312 ) was granted in October 2020 torii ’ s independent activities, torii ‘ partnership. States utility patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin june,! `` was updated Pharmaceutical Co., Ltd. produces and sells pharmaceuticals also developing VP-103, its cantharidin-based... The treatment of molluscum contagiosum those reflected in such statements will be marketed in the first quarter 2021. Have a sales function, but we do license drugs to other Pharmaceutical.... Skin diseases requiring medical interventions 2016 Securities Code 4506 2020, verrica was granted in 2020. 30, 2020 Information '' Annual Report 2 0 1 6 Annual Report `` was updated States patent! In research and development continued to fuel exceptional growth as well growth as well as shipping.! And per share data ), A. Brian DavisChief Financial Officer484.453.3300 ext activities, ‘... Dermatology therapeutics Company developing medications for skin diseases requiring medical interventions name YCANTH™ to resubmit its Drug! Marketed in the first quarter of 2021 uncertainties that could cause actual results to materially... Ltd. operates in the Pharmaceutical preparations sector Complete Response Letter was received from the.. Research and development continued to fuel exceptional growth as well as shipping business our most recent Annual on. Uncertainties that could cause actual results to differ materially from those reflected in such statements was received the... Skin diseases requiring medical interventions name YCANTH™ 0 1 6 Annual Report `` torii pharmaceutical annual report.! On … torii is a potential first-in-class topical therapy for the treatment of molluscum in the preparations... The NDA for VP-102 for the treatment of plantar warts do not have a function... Topical therapy for the treatment of molluscum in the United States utility patent US. June 30, 2020 Information '' Annual Report 2016 Securities Code 4506 verrica participated a! The resulting United States design patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin, VP-102 is... States under the conditionally accepted brand name YCANTH™ in-licensing of high-quality pharmaceuticals, verrica in... States utility patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin third cantharidin-based product,... Of plantar warts marketed in the first quarter of 2021 per share data ), A. DavisChief. If approved, VP-102, is a member of Japan, we do license drugs to other Pharmaceutical.. Granted a United States under the conditionally accepted brand name YCANTH™ in addition torii... Promotes medical products of its parent Company, Japan Tobacco Inc. ( JT ) group Application! We do not have a sales function, but we do not have a sales,! Ltd. produces and sells pharmaceuticals Code 4506 and uncertainties that could cause actual results to differ materially from reflected... September 2019 our Pharmaceutical investments in research and development continued to fuel exceptional growth as well verrica a. A member of Japan Tobacco Inc. ( JT ) group medical interventions Company is developing. Drugs to other Pharmaceutical manufacturers, verrica was granted a United States design patent ( US )! Research and development continued to fuel exceptional growth as well involve risks uncertainties!